- Market Capitalization, $K 337,506
- Shares Outstanding, K 203,317
- Annual Sales, $ 460 K
- Annual Income, $ -68,550 K
- 60-Month Beta 1.68
- Price/Sales 760.23
- Price/Cash Flow N/A
- Price/Book 2.85
|Period||Period Low||Period High||Performance|
| || |
-0.4700 (-22.07%)since 07/06/20
| || |
+0.4200 (+33.87%)since 05/06/20
| || |
+0.4700 (+39.50%)since 08/06/19
MENLO PARK, Calif. (AP) _ Geron Corp. (GERN) on Thursday reported a loss of $15.8 million in its second quarter.
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2020. The Company will host a conference call today...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will participate in a fireside chat...
Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2020 financial results after the market closes on Thursday, August 6, 2020 via press release, which will be available...
Geron has been struggling lately, but the selling pressure may be coming to an end soon
Geron has been struggling lately, but the selling pressure may be coming to an end soon.
Is (GERN) Outperforming Other Medical Stocks This Year?
Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 150,000 shares of Geron common stock as an inducement to a newly-hired employee...
Zealand's (ZEAL) partner, Boehringer Ingelheim, is developing BI 456906, a long-acting GLP-1/glucagon dual agonist, as a treatment for obesity and type 2 diabetes.
As of late, it has definitely been a great time to be an investor in Geron.
|Bioshares Biotech Clinical Trial|
|U.S. Liquidity Factor Vanguard ETF|
|Micro-Cap Ishares ETF|
|USA Min Vol Small-Cap Ishares Edge MSCI ETF|
|U.S. Momentum Factor Vanguard ETF|